A recently approved vaccine, nirsevimab, has shown to be 80% effective in preventing hospitalizations from RSV in individuals aged 60 and older. The vaccine, a long-acting monoclonal antibody, is also recommended for infants and young children to protect against RSV-associated lower respiratory tract infections.
who was in the intensive care unit of the pediatric clinic at St. Joseph Hospital with a respiratory syncytial infection and was receiving non-invasive ventilation . Photo: Christoph Soeder/dpa from the Centers for Disease Control and Prevention, respiratory syncytial virus activity continues to rise nationwide, with pediatric hospitalizations increasing across most of the country.
The Food and Drug Administration approved nirsevimab in July 2023. It is a long-acting monoclonal antibody, to be used to prevent RSV-associated lower respiratory tract infection among infants and young children. Nirsevimab works differently from a traditional vaccine. The monoclonal antibody provides passive immunization. In the case of vaccination, the body produces antibodies after a shot. With passive immunization, these antibodies are already in the jab.
The CDC’s Advisory Committee on Immunization Practices recommended nirsevimab in August 2023 for infants under the age of eight months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children between eight and 19 months of age at increased risk for severe RSV disease.that slightly more than half of U.S. of infants are currently protected from RSV by either direct administration of nirsevimab or maternal vaccination.
Not having nirsevimab available coupled with high levels of RSV incidence can put pressure on hospital capacity as yesterday’s report from the Netherlands suggests. Dutch hospitals have this week temporarily suspended certain procedures for children, such as heart operations. According to the Dutch news site, NOS, thein the country currently have a relatively high number of children with serious respiratory problems due to the RSV virus.
Last year, the Dutch government’s Health Council recommended offering all babies in the Netherlands nirsevimab in their first year of life. But the vaccine is still not available in the country. Health authorities hope that as soon as it does become accessible this year, as many parents as possible will sign up to have their children immunized. The Dutch public health agency expects the vaccine to prevent roughlyOur community is about connecting people through open and thoughtful conversations.
RSV Vaccine Infants Children Health
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Vaccine rollout to avoid 'tripledemic' of RSV, flu and COVIDThe NHS in Humber and North Yorkshire is offering the vaccines to pregnant women and older people.
Read more »
RSV Vaccine Research in Infants May Proceed With CautionFDA Committee discussed safety concerns but agreed that more data are needed.
Read more »
Public Acceptance of RSV Vaccine GrowsA new study shows increasing public acceptance of the RSV vaccine, while hesitancy appears to have stabilized.
Read more »
Has RSV Vaccine Hesitancy Subsided?More Americans believe in the effectiveness of vaccines developed to protect newborns and seniors against respiratory syncytial virus (RSV).
Read more »
Immunocompromised Older Adults Show Weaker RSV Vaccine ResponseA study by Johns Hopkins Medicine reveals that older adults with weakened immune systems produce fewer antibodies against RSV after vaccination compared to their healthy peers. More research is needed to understand this disparity and develop strategies to enhance their immune response.
Read more »
RSVpreF Vaccine Highly Effective in Preventing Severe RSV Illness in Older AdultsA new study shows that the RSVpreF vaccine is highly effective in preventing severe respiratory syncytial virus (RSV) illness in older adults. The vaccine was found to reduce the risk of hospitalization or emergency department visits by 90% to 91% in this population.
Read more »